Clinical Trial Update: A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Tividenofusp alfa (DNL310) in pediatric participants with Mucopolysaccharidosis II (Hunter syndrome) conducted by Denali T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Ii

Drugs mentioned

• Tividenofusp alfa (tividenofusp alfa)

Snippet

Sponsor: Denali Therapeutics Inc. | Conditions: Mucopolysaccharidosis II | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING